It's possible that because Dan O'Connor has done a number of weak give-away deals (Aratana, Biocon, Asia, Canada) Merck doesn't take him seriously at the negotiating table. Hope that's not the case and we're about to see a big deal unveiled that resets our valuation back up and adds context/justification to the latest non-performance-based management share grab.